Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668268 | 0.92 | KMT2A (0.36) | KDM4EMEN1KMT2AMAPTPRMT5 | |
| Trifluoroacetic Acid SCHEMBL711518 | 0.91 | PDE4A (0.36) | NOS1FFAR1 | |
| Trifluoroacetic Acid SCHEMBL709575 | 0.91 | SYK (0.34) | NOS1NOS3FFAR1KDM4EMEN1 | |
| Trifluoroacetic Acid SCHEMBL712600 | 0.89 | FAAH (0.38) | NOS1FFAR1SYK | |
| Trifluoroacetic Acid SCHEMBL709074 | 0.88 | NAMPT (0.36) | NOS1KDM4EMEN1KMT2AMAPT | |
| Trifluoroacetic Acid SCHEMBL718789 | 0.88 | PDE4A (0.35) | FFAR1KDM4EMEN1KMT2ACHEK2 | |
| Trifluoroacetic Acid SCHEMBL712920 | 0.88 | KDM4E (0.38) | NOS1FFAR1KDM4EMAPTCHEK2 | |
| Trifluoroacetic Acid SCHEMBL711889 | 0.88 | HDAC3 (0.34) | SYK | |
| Trifluoroacetic Acid SCHEMBL708256 | 0.87 | GUCY1B2 (0.36) | GPR6KDM4EMEN1KMT2ASYK | |
| Trifluoroacetic Acid SCHEMBL711960 | 0.87 | LMNA (0.37) | NOS1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | NOS1 3126/4885DHODH 910/4885GPR6 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.